Abstract: The present invention discloses anti-PD-L/PD-1 Axis antibody conjugates for targeted immunotherapy, as well as compositions comprising said conjugates. Further, the present invention discloses the use of the conjugates in the treatment of tumor/cancer.

Abstract: A filament lamp set in a drink bottle is provided, including a light emitting unit, wherein the outer side of the light emitting unit is sleeved by a connecting mechanism which can be fixedly connected with the mouth of a bottle body; an opening is formed in at least one end of the connecting mechanism; the light emitting unit extends out from the opening. The bottle body adopts the common drink bottle, by which the connecting mechanism can be matched with the mouth of the bottle so as to fix the bottle body in the connecting mechanism. In addition, the light emitting unit is sleeved by the bottle body. Based on the decorative patterns, colors and the like on the bottle body, different effects can be achieved by the emitted light and faculae, thus achieving the purpose of decoration.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: The present invention relates to therapeutic combinations and methods for treating cancers using combination therapy.

Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of HER2 positive tumors/cancers. Also provided are compositions comprising the compounds.

Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of EGFR expressing tumors/cancers. Also provided are compositions comprising the compounds.

Abstract: Provided are compounds for targeted immunotherapy. The compounds are useful in the treatment of diseases such as cancer. Also provided are compositions comprising the compounds.

Abstract: Compounds for targeted immunotherapy, compositions comprising the compounds and use of the compounds in the treatment of diseases such as cancer are disclosed. The compounds having the structure of formula TM-Ln-AM, wherein TM is a targeting moiety, AM is an activating moiety that is capable of activating a human dendritic cell, NK cell, or tumor cell, or a combination thereof, Ln is a linker, and n is an integer selected from 0 and 1.

Abstract: The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP.

Abstract: The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP.

Abstract: The prevalence of identical vulnerabilities across software monocultures has emerged as the biggest challenge for protecting the Internet from large-scale attacks against system applications. Artificially introduced software diversity provides a suitable defense against this threat, since it can potentially eliminate common-mode vulnerabilities across these systems. Systems and methods are provided that overcomes these challenges to support address-space randomization of the Windows® operating system. These techniques provide effectiveness against a wide range of attacks.

Abstract: The invention includes a method for testing a spreadsheet cell. Du-associations are collected for the spreadsheet cell. The cell's execution trace is tracked. After the user validates the cell, the du-associations that participated in the execution trace are marked as executed. Du-associations for other cells that are affected by the testing a spreadsheet cell are similarly marking as exercised. If the user changes a cell's contents, the collected du-associations for the cell are discarded and the steps of collecting test elements, tracking execution traces, and marking are repeated. Cells that depend on the changed cell also repeat these steps. After the user marks a cell as validated, a validation symbol is shown on the cell. If the cell's validation status is later brought into question, the validation symbol can change or be removed entirely. The invention also includes a method for providing a user with feedback of the testedness of the spreadsheet cells.